Cambridge Institute for Therapeutic Immunology and Infectious Disease

Cambridge Institute for Therapeutic Immunology and Infectious Disease
Name	Cambridge Institute for Therapeutic Immunology and Infectious Disease
Established	2019
Type	Research institute
Location	Cambridge, United Kingdom
Parent	University of Cambridge
Director	Wendy Barclay
Campus	Addenbrooke's

Cambridge Institute for Therapeutic Immunology and Infectious Disease The Cambridge Institute for Therapeutic Immunology and Infectious Disease is a multidisciplinary biomedical research centre within the University of Cambridge focused on translational immunology and infectious disease research. Founded to bridge basic science and clinical application, the institute integrates expertise from university departments, clinical centres, and biotechnology partners to accelerate therapeutics development. Its mission aligns with national and international initiatives to respond to emerging pathogens and immune-mediated diseases.

History

The institute was launched with strategic investments influenced by stakeholders including the Wellcome Trust, the National Institute for Health and Care Research, and philanthropic donors such as the Gates Foundation and the Royal Society. Early planning convened leaders from the Addenbrooke's Hospital clinical teams, the Department of Medicine, University of Cambridge, and the MRC Laboratory of Molecular Biology. Founding workshops referenced frameworks from the World Health Organization pandemic preparedness reports and drew on models used by the Francis Crick Institute and the Broad Institute. Seed projects emphasized rapid vaccine translation a la collaborations seen between the NIHR Cambridge Biomedical Research Centre and industrial partners like AstraZeneca and GlaxoSmithKline. The institute’s development paralleled responses to the COVID-19 pandemic and subsequent policy reviews by UK Research and Innovation.

Research Areas and Programs

Research programs span therapeutic immunology, viral pathogenesis, bacterial resistance, and immune engineering, integrating platforms such as single-cell genomics and structural biology. Programs link investigators from the Department of Pathology, University of Cambridge, the Department of Veterinary Medicine, University of Cambridge, and the Cambridge Institute for Medical Research. Projects include antiviral drug discovery reminiscent of efforts at Imperial College London and vaccine immunogenicity studies comparable to those at the University of Oxford and the Scripps Research Institute. Translational pipelines incorporate expertise from the Cambridge Biomedical Campus, including links to the Cancer Research UK Cambridge Institute and the MRC Mitochondrial Biology Unit. The institute also runs initiatives in antimicrobial stewardship, drawing on collaborations with the Royal College of Physicians and policy input from the Nuffield Trust.

Facilities and Infrastructure

Laboratory infrastructure includes BSL‑3 containment suites, high‑throughput screening facilities, and cryo-electron microscopy suites modeled after installations at the Diamond Light Source and the European Molecular Biology Laboratory. Core facilities provide mass spectrometry, flow cytometry, and computational clusters integrated with resources from the Cambridge Centre for Data‑Driven Discovery and the European Bioinformatics Institute. The institute’s proximity to clinical space on the Addenbrooke's Hospital site enables translational studies and clinical trials coordinated with the Cambridge Clinical Trials Unit and partnerships with pharmaceutical partners such as Moderna and Pfizer. Shared facilities are managed in coordination with the Wellcome Sanger Institute and regional consortia that include the East of England Academic Health Science Network.

Collaborations and Partnerships

The institute maintains formal collaborations with international research centres including the Pasteur Institute, the Max Planck Society, and the National Institutes of Health. Industry partnerships span multinational pharmaceutical firms and biotech firms including AstraZeneca, GSK, Moderna, and numerous Cambridge‑based spinouts such as those from Cambridge Enterprise and the Babraham Research Campus. Consortia extend to global health organizations like the Coalition for Epidemic Preparedness Innovations and clinical networks including the International Severe Acute Respiratory and Emerging Infection Consortium. Academic collaborations include joint grants with the University of Oxford, Imperial College London, King's College London, and the University of Edinburgh.

Education and Training

The institute contributes to postgraduate education through PhD studentships and postdoctoral fellowships administered via the Wellcome Trust PhD Programme, the European Molecular Biology Organization fellowships, and the NIHR Doctoral Research Fellowship pathway. Training programs include clinical fellowships in infectious disease and immunology coordinated with the Cambridge School of Clinical Medicine and undergraduate opportunities via the Department of Biochemistry, University of Cambridge and the Department of Chemical Engineering and Biotechnology, University of Cambridge. Professional development courses leverage partnerships with the European Centre for Disease Prevention and Control and the London School of Hygiene & Tropical Medicine.

Leadership and Governance

Governance is overseen by a board comprising representatives from the University of Cambridge, clinical partners at Cambridge University Hospitals NHS Foundation Trust, and funders such as the Wellcome Trust and UK Research and Innovation. Scientific leadership includes directors and programme heads with affiliations to the MRC Laboratory of Molecular Biology, the Cambridge Institute for Medical Research, and the Cancer Research UK Cambridge Institute. Advisory input is provided by international experts from institutions such as the Harvard T.H. Chan School of Public Health, the Johns Hopkins Bloomberg School of Public Health, and the Yale School of Medicine.

Impact and Notable Contributions

Since inception, the institute has contributed to antiviral candidate pipelines, rapid diagnostic development, and mechanistic insights into immune correlates of protection, partnering on studies comparable to those published by teams at the University of Oxford and the NIH Vaccine Research Center. Collaborative work has informed policy discussions in forums including the World Health Assembly and supported technology transfer efforts aligned with the Medicines and Healthcare products Regulatory Agency. The institute has catalysed spinouts and translational projects that mirror successes of the Babraham Research Campus and bolstered regional capacity for outbreak response alongside the UK Health Security Agency.

Category:Research institutes in Cambridge